Adamis Pharmaceuticals Corporation

0.1152-0.0048-4.00%Vol 219.66K1Y Perf -80.01%
Mar 24th, 2023 12:28 DELAYED
BID0.1152 ASK0.1196
Open0.1164 Previous Close0.1200
Pre-Market0.12 After-Market-
 0.00 -1.67%  - -
Target Price
1.25 
Analyst Rating
— 0.00
Potential %
985.07 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
     30.18
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
     34.92
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.99 
Earnings Rating
Buy
Market Cap19.18M 
Earnings Date
15th May 2023
Alpha-0.01 Standard Deviation0.32
Beta1.19 

Today's Price Range

0.11090.1200

52W Range

0.09920.6350

5 Year PE Ratio Range

-2.30-2.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
9.09%
1 Month
-56.83%
3 Months
-23.08%
6 Months
-48.98%
1 Year
-80.01%
3 Years
-69.23%
5 Years
-96.57%
10 Years
-98.91%

TickerPriceChg.Chg.%
ADMP0.1152-0.0048-4.00
AAPL158.53-0.4000-0.25
GOOG105.40-0.8600-0.81
MSFT277.780.11540.04
XOM102.93-0.4800-0.46
WFC35.70-0.9150-2.50
JNJ151.980.84500.56
FB196.640.99000.51
GE91.740.15000.16
JPM124.13-2.7100-2.14
 
ProfitabilityValueIndustryS&P 500US Markets
-271.40
-2 090.60
-1 988.50
-236.20
-
RevenueValueIndustryS&P 500US Markets
2.61M
0.02
-28.04
-5.39
Earnings HistoryEstimateReportedSurprise %
Q03 2022--0.03-
Q02 2022-0.04-0.06-50.00
Q01 2022-0.03-0.07-133.33
Q03 2021-0.06-0.0350.00
Q04 2020--0.16-
Q03 2020-0.04-0.10-150.00
Q02 2020-0.07-0.13-85.71
Q01 2020-0.05-0.10-100.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.040.00-
9/2022 QR-0.030.00-
12/2022 FY-0.15-15.38Negative
12/2023 FY-0.06-20.00Negative
Next Report Date15th May 2023
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume219.66K
Shares Outstanding166.48K
Shares Float149.41M
Trades Count453
Dollar Volume25.30K
Avg. Volume1.61M
Avg. Weekly Volume1.35M
Avg. Monthly Volume2.34M
Avg. Quarterly Volume1.15M

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock closed at 0.12 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 712.26K shares and market capitalization of 19.18M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 171 people. Adamis Pharmaceuticals Corporation CEO is Dennis J. Carlo.

The one-year performance of Adamis Pharmaceuticals Corporation stock is -80.01%, while year-to-date (YTD) performance is -29.12%. ADMP stock has a five-year performance of -96.57%. Its 52-week range is between 0.0992 and 0.635, which gives ADMP stock a 52-week price range ratio of 2.99%

Adamis Pharmaceuticals Corporation currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 10.38, a price-to-sale (PS) ratio of 11.62, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -126.88%, a ROC of -164.56% and a ROE of -199.24%. The company’s profit margin is -%, its EBITDA margin is -1 988.50%, and its revenue ttm is $2.61 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Adamis Pharmaceuticals Corporation, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Adamis Pharmaceuticals Corporation’s next earnings report date is 15th May 2023.

The consensus rating of Wall Street analysts for Adamis Pharmaceuticals Corporation is (0), with a target price of $1.25, which is +985.07% compared to the current price. The earnings rating for Adamis Pharmaceuticals Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamis Pharmaceuticals Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamis Pharmaceuticals Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 23.51, ATR14 : 0.02, CCI20 : -64.85, Chaikin Money Flow : -0.55, MACD : -0.03, Money Flow Index : 20.40, ROC : -23.08, RSI : 34.14, STOCH (14,3) : 30.06, STOCH RSI : 1.00, UO : 38.95, Williams %R : -69.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamis Pharmaceuticals Corporation in the last 12-months were: Dennis J. Carlo (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Hold
3.00

Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose. Its SYMJEPI (epinephrine) Injection products are used in the emergency treatment of acute allergic reactions, including anaphylaxis.

CEO: Dennis J. Carlo

Telephone: +1 858 997-2400

Address: 11682 El Camino Real, San Diego 92130, CA, US

Number of employees: 171

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

60%40%

Bearish Bullish

62%38%


News

Stocktwits